Clinical Efficacy of Amoxicillin and Clavulanate Potassium in the Treatment of Tonsillitis and its Effect on the Levels of PCT,TNF-α and IL-6
Objective To analyze the clinical efficacy of amoxicillin and clavulanate potassium in the treatment of tonsillitis and its effect on the levels of PCT,TNF-α and IL-6.Methods A total of 56 patients with tonsillitis diagnosed and treated in our hospital from March 2022 to January 2023 were selected as the research objects.They were divided into observation group and control group by random number table method,with 28 patients in each group.The control group was treated with amoxicillin,and the observation group was treated with amoxicillin and clavulanate potassium.The clinical efficacy,symptom regression time,inflammatory factor levels[procalcitonin(PCT)and interleukin-6(IL-6)levels,tumor necrosis factor-α(TNF-α)]and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 92.86％,which was higher than 82.14％in the control group(P＜0.05).The regression time of fever,tonsil congestion,sore throat and throat abscess in the observation group was shorter than that in the control group(P＜0.05).After treatment,the levels of PCT,IL-6 and TNF-α in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(P＜0.05).The incidence of adverse reactions in the observation group was 7.14％,which was lower than 21.43％in the control group(P＜0.05).Conclusion Amoxicillin and clavulanate potassium is effective and safe in the treatment of tonsillitis,which can improve the clinical efficacy,reduce the incidence of adverse reactions,promote the reduction of inflammatory factor levels.Meanwhile,it can quickly reduce clinical symptoms,and have a positive impact on the rehabilitation of patients.
Amoxicillin and clavulanate potassiumTonsillitisPCTTNF-αIL-6
万方数据
维普
